Skip to main content
OpenTrials
Completed

NCT Number: NCT02142634

Budesonide for Induction of Remission in Incomplete Microscopic Colitis

The purpose of this study is to demonstrate the efficacy of budesonide for the treatment of active incomplete microscopic colitis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Centre for Digestive Diseases, Hamburg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically established diagnosis of incomplete microscopic colitis (MCi)
  • History of chronic non-bloody, watery diarrhoea
  • Clinically active disease

Exclusion criteria

  • Other significant abnormalities in colonoscopy
  • Infectious cause of diarrhoea
  • Clinical suspicion of drug-induced diarrhoea
  • Prior and present MC
  • History of bowel resection
  • Radiation therapy of the abdominal or pelvic region
  • Positive antibody titres for celiac disease
  • Untreated active thyroid dysfunction
  • Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder reducing life expectancy
  • Abnormal hepatic function
  • Tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, or infection if careful medical monitoring is not ensured
  • History of colorectal cancer
  • History of cancer (other than colorectal) in the last 5 years
  • Therapy with immunomodulators/budesonide or other steroids/antibiotics/anti-diarrhoeal drugs
  • Current or intended pregnancy or breast-feeding
  • Doubt about the patient's cooperation, e.g. because of addiction to alcohol or drugs
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

Treatment and study plan

Budesonide granules 9 mg

Drug

per day

Placebo granules

Drug

per day

Primary outcomes

  1. Rate of clinical remission

    Time frame: 8 weeks

Secondary outcomes

  1. Rate of clinical remission

    Time frame: 2 weeks

  2. Rate of clinical remission

    Time frame: 6 weeks

  3. Time to remission

    Time frame: 8 weeks

  4. Number of formed/soft/watery stools per week

    Time frame: 8 weeks

  5. Number of days with abdominal pain

    Time frame: 8 weeks

  6. Number of days with urgency

    Time frame: 8 weeks

  7. Rate of histological remission

    Time frame: 8 weeks

  8. Physician's global assessment at final visit

    Time frame: 8 weeks

  9. Quality of life

    Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Dr. Falk Pharma GmbH

Industry

Registry information

Official study title

Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis

Important dates

Study start
2014
Primary completion
2020
Study completion
2020
First posted
May 20, 2014
Registry last updated
Jul 22, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.